Lung function and long-term safety of tiotropium/olodaterol in East Asian patients with chronic obstructive pulmonary disease

References

• Global Initiative for Chronic Obstructive Lung DiseaseGlobal Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2016 Report Available from: http://goldcopd.org/global-strategy-diagnosis-management-prevention-copd-2016/Accessed April 27, 2016
   Google Scholar
• CasaburiRMahlerDAJonesPWA long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary diseaseEur Respir J200219221722411866001
   PubMed Web of Science ®Google Scholar
• O’DonnellDEFlugeTGerkenFEffects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPDEur Respir J200423683284015218994
   PubMed Web of Science ®Google Scholar
• MaltaisFHamiltonAMarciniukDImprovements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPDChest200512831168117816162703
   PubMed Web of Science ®Google Scholar
• TashkinDPCelliBSennSA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med2008359151543155418836213
   PubMed Web of Science ®Google Scholar
• BatemanEDTashkinDSiafakasNA one-year trial of tiotropium Respimat plus usual therapy in COPD patientsRespir Med2010104101460147220620037
   PubMed Web of Science ®Google Scholar
• YohannesAMWillgossTGVestboJTiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomesRespir Care201156447748721255503
   PubMed Web of Science ®Google Scholar
• VogelmeierCHedererBGlaabTTiotropium versus salmeterol for the prevention of exacerbations of COPDN Engl J Med2011364121093110321428765
   PubMed Web of Science ®Google Scholar
• FergusonGTFeldmanGJHofbauerPEfficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2–4 COPD: results from two replicate 48-week studiesInt J Chron Obstruct Pulmon Dis2014962964524966672
   PubMed Web of Science ®Google Scholar
• KochAPizzichiniEHamiltonALung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studiesInt J Chron Obstruct Pulmon Dis2014969771425045258
   PubMed Web of Science ®Google Scholar
• FeldmanGJBernsteinJAHamiltonANivensMCKorduckiLLaForceCThe 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2–4 COPD: results from two 6-week crossover studiesSpringerplus20143141925187881
   PubMedGoogle Scholar
• LangePAumannJHamiltonATetzlaffKTingNThe 24-hour lung function time profile of olodaterol once daily versus placebo and tiotropium in patients with moderate to very severe chronic obstructive pulmonary diseaseJ Pulm Respir Med201444196
   Google Scholar
• BuhlRMaltaisFAbrahamsRTiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)Eur Respir J201545496997925573406
   PubMed Web of Science ®Google Scholar
• CazzolaMRoglianiPOraJMateraMGOlodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary diseaseExpert Rev Clin Pharmacol20158552953926294073
   PubMed Web of Science ®Google Scholar
• SinghDFergusonGTBolitschekJTiotropium + olodaterol shows clinically meaningful improvements in quality of lifeRespir Med2015109101312131926320402
   PubMed Web of Science ®Google Scholar
• BeehKMWestermanJKirstenAMThe 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary diseasePulm Pharmacol Ther201532535925956072
   PubMed Web of Science ®Google Scholar
• BeehKMDeromEEchave-SustaetaJThe lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler® (ENERGITO® study)Int J Chron Obstruct Pulmon Dis20161119320526893551
   PubMed Web of Science ®Google Scholar
• FergusonGTFlezarMKornSEfficacy of tiotropium + olodaterol in patients with chronic obstructive pulmonary disease by initial disease severity and treatment intensity: a post hoc analysisAdv Ther201532652353626112656
   PubMed Web of Science ®Google Scholar
• SahooUBasic principlesClinical Research in Asia: Opportunities and ChallengesCambridgeWoodhead Publishing Ltd20124546
   Google Scholar
• SerebruanyVLTomekAPyaYBekbossynovaMKimMHInferiority of ticagrelor in the PHILO trial: play of chance in East Asians or nightmare confirmation of PLATO-USA?Int J Cardiol201621537237627128564
   PubMed Web of Science ®Google Scholar
• YanoRKonnoAWatanabeKPharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trialsInt J Clin Oncol20131819610422095245
   PubMed Web of Science ®Google Scholar
• HuangCELuCHChenPTEfficacy and safety of dose-modified docetaxel plus cisplatin-based induction chemotherapy in Asian patients with locally advanced head and neck cancerJ Clin Pharm Ther201237334234721950487
   PubMed Web of Science ®Google Scholar
• WangHMLinCYHsiehCHInduction chemotherapy with dose-modified docetaxel, cisplatin, and 5-fluorouracil in Asian patients with borderline resectable or unresectable head and neck cancerJ Formos Med Assoc2017116318518927133181
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyICH Topic E 11 Clinical Investigation of Medicinal Products in the Paediatric Population Available: http://www.ema.europa.eu/docs/en_GB/document_library/Scien-tific_guideline/2009/09/WC500002926.pdfAccessed September 12, 2016
   Google Scholar
• YasudaSUZhangLHuangSMThe role of ethnicity in variability in response to drugs: focus on clinical pharmacology studiesClin Pharmacol Ther200884341742318615002
   PubMed Web of Science ®Google Scholar
• NgMFreemanMKFlemingTDSmoking prevalence and cigarette consumption in 187 countries, 1980–2012JAMA2014311218319224399557
   PubMed Web of Science ®Google Scholar
• JonesPWAndersonJACalverleyPMHealth status in the TORCH study of COPD: treatment efficacy and other determinants of changeRespir Res20111217121627828
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim International GmbHSpiolto Respimat 2.5 microgram/2.5 microgram, inhalation solution. Summary of product characteristics, labelling and package leaflet 2015 Available from: http://mri.medagencies.org/download/NL_H_3157_001_FinalPI.pdfAccessed March 1, 2016
   Google Scholar
• TangYMasseyDZhongNSEvaluation of the efficacy and safety of tiotropium bromide (5 microg) inhaled via Respimat in Chinese patients with chronic obstructive pulmonary diseaseChin Med J (Engl)2013126193603360724112149
   PubMed Web of Science ®Google Scholar
• DecramerMJanssensWChronic obstructive pulmonary disease and comorbiditiesLancet Respir Med201311738324321806
   PubMed Web of Science ®Google Scholar
• NegewoNAGibsonPGMcDonaldVMCOPD and its comorbidities: impact, measurement and mechanismsRespirology20152081160117126374280
   PubMed Web of Science ®Google Scholar